The endocrine effects of long-term oral opioid therapy: A case report and review of the literature

Journal of Opioid Management

Volumn 7, Issue 2, 2011, Pages 145-154

  Elliott, Jennifer A ^a   Horton, Erica ^a   Fibuch, Eugene E ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endocrine; Hypogonadism; Opioids; Osteoporosis; Testosterone

Indexed keywords

HYDROMORPHONE; MORPHINE; OXYCODONE; OXYMORPHONE;

AGED; ARTICLE; CASE REPORT; DEPRESSION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOCRINE DISEASE; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; IMPOTENCE; LIBIDO DISORDER; LOW BACK PAIN; MALE; MIGRAINE; RADICULAR PAIN;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; OSTEOPOROSIS; TESTOSTERONE;

EID: 79955941856     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2011.0057     Document Type: Article

References (59)

1. Colamenco C, Coren JS: Opioid-induced endocrinopathy. J Am Osteopath Assoc. 2009; 109(1): 20-25.
2. Fraser L-A, Morrison D, Morley-Forster P, et al.: Oral opioids for chronic non-cancer pain: Higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes. 2009; 117: 38-43.
3. Finch PM, Roberts LJ, Price LS, et al.: Hypogonadism in patients treated with intrathecal morphine. Clin J Pain. 2000; 16(3): 251-254.
4. Paice JA, Penn RD, Ryan WG: Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manage. 1994; 9(2): 126-131. (Pubitemid 24105187)
5. Abs R, Verhelst J, Maeyaert J, et al.: Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000; 85(6): 2215-2222. (Pubitemid 32269246)
6. Roberts LJ, Finch PM, Goucke CR, et al.: Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain. 2001; 5: 353-361. (Pubitemid 34072462)
7. Roberts LJ, Finch PM, Pullan PT, et al.: Sex hormone suppression by intrathecal opioids: A prospective study. Clin J Pain. 2002; 18: 144-148. (Pubitemid 34475593)
8. Bolelli G, Lafisca S, Flamigni C, et al.: Heroin addiction: Relationship between the plasma levels of testosterone, dihydrotestosterone, androstenedione, LH, FSH, and the plasma concentration of heroin. Toxicology. 1979; 15: 19-29. (Pubitemid 10134450)
9. Daniell HW: Narcotic-induced hypogonadism during therapy for heroin addiction. J Addict Dis. 2002; 21(4): 47-53.
10. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al.: Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. J Pain Symptom Manage. 2003; 26(5): 1055-1061. (Pubitemid 37324686)
11. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al.: Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004; 100(4): 851-858. (Pubitemid 38176866)
12. Daniell HW: Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002; 3(5): 377-384.
13. Daniell HW: Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008; 9(1): 28-36.
14. Daniell HW, Lentz R, Mazer NA: Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain. 2006; 7(3): 200-210. (Pubitemid 43324996)
15. Katz N: The impact of opioids on the endocrine system. Pain Manage Rounds. 2005; 1(9).
16. Katz N, Mazer NA: The impact of opioids on the endocrine system. Clin J Pain. 2009; 25(2): 170-175.
17. Merck Manual Professional: Male hypogonadism: Male endocrinology. Available at www.merck.com/mmpe/sec17/ch227/ch227b.html. Accessed August 30, 2010.
18. Snyder PJ: Causes of secondary hypogonadism in males. In Martin KA (ed.): Up To Date. Waltham, MA: UpToDate, 2010.
19. Brydoy M, Fossa SD, Dahl O, et al.: Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol. 2007; 46(4): 480-489. (Pubitemid 46752258)
20. Hayes FJ, Bubley GJ: Effects of cytotoxic agents on gonadal function in adult men. In Martin KD (ed.): Up To Date. Waltham, MA: UpToDate, 2010.
21. Pfeilschifter J, Diel IJ: Osteoporosis due to cancer treatment: Pathogenesis and management. J Clin Oncol. 2000; 18(7): 1570-1593.
22. Kiserud CE, Schover LR, Dahl AA, et al.: Do male lymphoma survivors have impaired sexual function? J Clin Oncol. 2009; 27(35): 6019-6026.
23. Rivkees SA, Crawford JD: The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988; 259(14): 2123-2125. (Pubitemid 18088500)
24. Miller KK, Sesmilo G, Schiller A, et al.: Androgen deficiency in women with hypopituitarism. J Clin Endocrinol Metab. 2001; 86(2): 561-567.
25. Bachmann G, Oza D: Female androgen insufficiency. Obstet Gynecol Clin North Am. 2006; 33: 589-598. (Pubitemid 44751390)
26. Daniell HW: DHEAS deficiency during consumption of sustained-action prescribed opioids: Evidence for opioid-induced inhibition of adrenal androgen production. J Pain. 2006; 7(12): 901-907.
27. Davis S: Testosterone deficiency in women. J Reprod Med. 2001; 46(3): 291-296.
28. Daniell HW: Sex hormone deficiency in depressed patients receiving opioids. Arch Intern Med. 2004; 164: 804 (Letter).
29. Schmidt PJ, Berlin KL, Danaceau MA, et al.: The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch Gen Psychiatry. 2004; 61: 997-1004. (Pubitemid 39336533)
30. Zarrouf FA, Artz S, Griffith J, et al.: Testosterone and depression: Systematic review and meta-analysis. J Psychiatr Pract. 2009; 15(4): 289-305.
31. Seidman SN, Orr G, Raviv G, et al.: Effects of testosterone replacement in middle-aged men with dysthymia: A randomized, placebo-controlled trial. J Clin Psychopharmacol. 2009; 29(3): 216-221.
32. Barrett-Connor E, von Muehlen DG, Kritz-Silverstein D: Bioavailable testosterone and depressed mood in older men: The Ranch Bernardo Study. J Clin Endocrinol Metab. 1999; 84: 573-577. (Pubitemid 29075686)
33. Pope HG, Cohane GH, Kanayama G, et al.: Testosterone gel supplementation for men with refractory depression: A randomized, placebo-controlled trial. Am J Psychiatry. 2003; 160: 105-111. (Pubitemid 36042433)
34. Finkelstein JS: Epidemiology and etiology of osteoporosis in men. In Mulder JE (ed.): Up To Date. Waltham, MA: UpToDate, 2010.
35. Holmes SJ, Whitehouse RW, Clark ST, et al.: Reduced bone mineral density in men following chemotherapy for Hodgkin's disease. Br J Cancer. 1994; 70: 371-375. (Pubitemid 24247165)
36. Pedrazzoni M, Vescovi PP, Maninetti L, et al.: Effects of chronic heroin abuse on bone and mineral metabolism. Acta Endocrinol. 1993; 129: 42-45. (Pubitemid 23225790)
37. Kim TW, Alford DP, Malabanan A, et al: Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend. 2006; 85: 258-262. (Pubitemid 44666285)
38. Khosla S, Melton LJ III, Atkinson EJ, et al.: Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001; 86(8): 3555-3561. (Pubitemid 32755943)
39. Miller KK: Androgen deficiency in women. J Clin Endocrinol Metab. 2001; 86(6): 2395-2401 (Commentary).
40. Davis S: Androgen replacement in women: A commentary. J Clin Endocrinol Metab. 1999; 84: 1886-1891.
41. Amin S, Zhang Y, Felson DT, et al: Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med. 2006; 119: 426-433.
42. Fink HA, Ewing SK, Ensrud KE, et al.: Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab. 2006; 91(10): 3908-3915. (Pubitemid 44536863)
43. Fortin JD, Bailey GM, Vilensky JA: Does opioid use for pain management warrant routine bone mass density screening in men? Pain Physician. 2008; 11: 539-541.
44. Daniell HW: Opioid osteoporosis. Arch Intern Med. 2004; 164: 338 (Letter).
45. Vuong C, Van Uum SHM, O'Dell LE, et al.: The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010; 31(1): 98-132.
46. Bachmann G, Bancroft J, Braunstein G, et al.: Female androgen insufficiency: The Princeton consensus statement on definition, classification, and assessment. Fertil Steril. 2002; 77(4): 660-665. (Pubitemid 34275339)
47. Arlt W: Androgen therapy in women. Eur J Endocrinol. 2006; 154: 1-11.
48. Daniell HW: Opioid-induced androgen deficiency discussion in opioid contracts. Am J Med. 2007; 120: e21 (Letter).
49. American Academy of Pain Medicine: Consent for chronic opioid therapy. Available at www.painmed.org/Workarea/DownloadAsset.aspx?id=3211. Accessed August 30, 2010.
50. Wierman ME, Basson R, Davis SR, et al.: Androgen therapy in women: An Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab. 2006; 91(10): 3697-3710. (Pubitemid 44536831)
51. Bhasin S, Cunningham GR, Hayes FJ, et al.: Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010; 95(6): 2536-2559.
52. Endocrinologist's Guidelines for the Diagnosis and Treatment of Menopause: Androgen deficiency in postmenopausal women. Available at www.medscape.com/viewarticle/540531-12. Accessed August 30, 2010.
53. Fernandez-Balsells MM, Murad MH, Lane M, et al.: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2010; 95: 2560-2575.
54. Basaria S, Coviello AD, Travison TG, et al.: Adverse events associated with testosterone administration. N Engl J Med. 2010; 363(2): 109-122.
55. Auernhammer CJ, Vlotides G: Anterior pituitary hormone replacement therapyÑA clinical review. Pituitary. 2007; 10: 1-15. (Pubitemid 46562803)
56. Snyder PJ: Testosterone treatment of male hypogonadism. In Marin KA (ed.): Up To Date. Waltham, MA: UpToDate, 2010.
57. Lexi-Comp Online: Testosterone. Lexi-Drugs Online. Lexi-Comp, Inc., 1978-2010. Available at www.lexi.com.
58. Mazer NA: Testosterone deficiency in women: Etiologies, diagnosis, and emerging treatments. Int J Fertil. 2002; 47(2): 77-86.
59. Tennant F: Testosterone replacement in female chronic pain patients. Pract Pain Manage. 2009; November/December: 25-27.